Skip to main content
SpringerLink
Log in

History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona

  • Chapter
  • First Online:
The First Outstanding 50 Years of “Università Politecnica delle Marche”

  • 334 Accesses

Abstract

Clinica Medica and Ematologica in Ancona stemmed some 30 years ago from one originator medical team dedicated to Internal Medicine practice with a special interest towards immunological and hematological studies. This original scientific interest has spread over a multitude of fellows, some of whom have reached outstanding academic and clinical results, maintaining and extending the excellent reputation of the founding group over the years and until the present time. The best scientific achievements have been obtained in the field of systemic sclerosis and chronic graft versus host disease, whereas the clinical activity has been successfully dedicated to the management of autoimmune diseases and hematological disorders, with particular attention to innovative immunomodulatory therapies and stem cell transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baroni SS, Santillo M, Bevilacqua F et al (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354:2667–2676

    Article  Google Scholar 

  2. Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360:1989–2003

    Article  Google Scholar 

  3. Moroncini G, Grieco A, Nacci G et al (2015) Epitope specificity determines pathogenicity and detectability of anti-platelet-derived growth factor receptor alpha autoantibodies in systemic sclerosis. Arthritis Rheumatol 67:1891–1903

    Article  Google Scholar 

  4. Moroncini G, Paolini C, Orlando F et al (2018) Mesenchymal stromal cells from human umbilical cord prevent the development of lung fibrosis in immunocompetent mice. PLoS ONE 13:e0196048

    Article  Google Scholar 

  5. Murgia F, Svegliati S, Poddighe S et al (2018) Metabolomic profile of systemic sclerosis patients. Sci Rep 8:7626

    Article  Google Scholar 

  6. Moroncini G, Svegliati Baroni S, Gabrielli A (2018) Agonistic antibodies in systemic sclerosis. Immunol Lett 195:83–87

    Article  Google Scholar 

  7. Patrone V, Puglisi E, Cardinali M et al (2017) Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep 7:14874

    Article  Google Scholar 

  8. Svegliati S, Amico D, Spadoni T et al (2017) Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro. Front Immunol 8:75

    Google Scholar 

  9. Moroncini G, Cuccioloni M, Mozzicafreddo M et al (2017) Characterization of binding and quantification of human autoantibodies to PDGFRalpha using a biosensor-based approach. Anal Biochem 528:26–33

    Article  Google Scholar 

  10. Luchetti MM, Moroncini G, Jose Escamez M et al (2016) Induction of scleroderma fibrosis in skin-humanized mice by administration of anti-platelet-derived growth factor receptor agonistic autoantibodies. Arthritis Rheumatol 68:2263–2273

    Article  Google Scholar 

  11. Svegliati S, Olivieri A, Campelli N et al (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110:237–241

    Article  Google Scholar 

  12. Svegliati S, Cancello R, Sambo P et al (2005) Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 280:36474–36482

    Article  Google Scholar 

  13. Avvedimento EV, Gabrielli A (2010) Stiff and tight skin: a rear window into fibrosis without inflammation. Sci Transl Med 2:23ps13

    Google Scholar 

  14. Bocchino M, Agnese S, Fagone E et al (2010) Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. PLoS ONE 5:e14003

    Article  Google Scholar 

  15. Smaldone S, Olivieri J, Gusella GL et al (2011) Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. Fibrogenesis Tissue Repair 4:8

    Article  Google Scholar 

  16. Spadoni T, Svegliati Baroni S, Amico D et al (2015) A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 67:1611–1622

    Article  Google Scholar 

  17. Svegliati S, Marrone G, Pezone A et al (2014) Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal 7: ra84

    Google Scholar 

  18. Olivieri A, Locatelli F, Zecca M et al (2009) Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 114:709–718

    Article  Google Scholar 

  19. Fraticelli P, De Vita S, Franzolini N et al (2015) Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. Clin Exp Rheumatol 33:S160–S167

    Google Scholar 

  20. Olivieri J, Manfredi L, Postacchini L et al (2015) Consensus recommendations for improvement of unmet clinical needs–the example of chronic graft-versus-host disease: a systematic review and meta-analysis. Lancet Haematol 2:e297–e305

    Article  Google Scholar 

  21. Fraticelli P, Gabrielli B, Pomponio G et al (2014) Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther 16:R144

    Article  Google Scholar 

  22. Iudici M, Moroncini G, Cipriani P et al (2015) Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? Autoimmun Rev 14:575–578

    Article  Google Scholar 

  23. Maurizi G, Mattiucci D, Mariani M et al (2017) DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype. Br J Haematol 177:818–822

    Article  Google Scholar 

  24. Poloni A, Maurizi G, Mattiucci D et al (2014) Overexpression of CDKN2B (p15INK4B) and altered global DNA methylation status in mesenchymal stem cells of high-risk myelodysplastic syndromes. Leukemia 28:2241–2244

    Article  Google Scholar 

  25. Poloni A, Serrani F, Berardinelli E et al (2013) Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome. Leuk Res 37:1538–1544

    Article  Google Scholar 

  26. Poloni A, Goteri G, Zizzi A et al (2013) Prognostic role of immunohistochemical analysis of 5 mc in myelodysplastic syndromes. Eur J Haematol 91:219–227

    Article  Google Scholar 

  27. Mattiucci D, Maurizi G, Leoni P et al (2018) Agingand senescence-associated changes of mesenchymal stromal cells in myelodysplastic syndromes. Cell Transplant 27:754–764

    Article  Google Scholar 

  28. Offidani M, Bringhen S, Corvatta L et al (2007) Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 78:297–302

    Article  Google Scholar 

  29. Offidani M, Corvatta L, Maracci L et al (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J 3:e162

    Article  Google Scholar 

  30. Nabissi M, Morelli MB, Offidani M et al (2016) Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration. Oncotarget 7:77543–77557

    Google Scholar 

  31. Morelli MB, Offidani M, Alesiani F et al (2014) The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2. Int J Cancer 134:2534–2546

    Article  Google Scholar 

  32. Rupoli S, Goteri G, Pulini S et al (2005) Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 75:136–145

    Article  Google Scholar 

  33. Rupoli S, Canafoglia L, Goteri G et al (2016) Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides. Eur J Dermatol 26:13–20

    Google Scholar 

  34. Olivieri J, Attolico I, Nuccorini R et al (2018) Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplant 53:461–473

    Article  Google Scholar 

  35. Olivieri A, Saraceni F (2016) Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean. Bone Marrow Transplant 51:348–350

    Article  Google Scholar 

  36. Saraceni F, Shem-Tov N, Olivieri A et al (2015) Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant 50:886–891

    Article  Google Scholar 

  37. Pierelli L, Berto P, Accorsi P et al (2013) The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Societa Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey. Transfus Apher Sci 49:615–622

    Article  Google Scholar 

  38. Lanza F, Lemoli RM, Olivieri A et al (2014) Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 54:331–339

    Google Scholar 

  39. Pierelli L, Perseghin P, Marchetti M et al (2012) Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Societa Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. Transfusion 52:893–905

    Article  Google Scholar 

  40. Attolico I, Pavone V, Ostuni A et al (2012) Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 18:241–249

    Article  Google Scholar 

  41. Olivieri A, Marchetti M, Lemoli R et al (2012) Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 47:342–351

    Article  Google Scholar 

  42. Olivieri A, Offidani M, Cantori I et al (1995) Addition of erythropoietin to granulocyte colony-stimulating factor after priming chemotherapy enhances hemopoietic progenitor mobilization. Bone Marrow Transplant 16:765–770

    Google Scholar 

  43. Olivieri A, Offidani M, Ciniero L et al (1995) DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. Bone Marrow Transplant 16:85–93

    Google Scholar 

  44. Saraceni F, Bruno B, Lemoli RM et al (2017) Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. Bone Marrow Transplant 52:163–166

    Article  Google Scholar 

  45. Martino M, Lemoli RM, Girmenia C et al (2016) Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplant 51:1032–1040

    Article  Google Scholar 

  46. Capelli D, Chiarucci M, Poloni A et al (2014) Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin. Biol Blood Marrow Transplant 20:1399–1406

    Article  Google Scholar 

  47. Martino M, Montanari M, Ferrara F et al (2014) Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. Biol Blood Marrow Transplant 20:1026–1032

    Article  Google Scholar 

  48. Perseghin P, Marchetti M, Pierelli L et al (2014) A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. Transfusion 54:2353–2360

    Article  Google Scholar 

  49. Martino M, Olivieri A, Offidani M et al (2013) Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs 22:619–634

    Article  Google Scholar 

  50. Martino M, Montanari M, Bruno B et al (2012) Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. Expert Opin Biol Ther 12:1449–1462

    Article  Google Scholar 

  51. Lemoli RM, D’addio A, Marotta G et al (2010) BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study. Bone Marrow Transplant 45:640–646

    Google Scholar 

  52. Olivieri A, Capelli D, Troiani E et al (2007) A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. Exp Hematol 35:1074–1082

    Article  Google Scholar 

  53. Olivieri A, Santini G, Patti C et al (2005) Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin’s lymphoma: long-term results by the NHLCSG. Ann Oncol 16:1941–1948

    Article  Google Scholar 

  54. Olivieri A, Lucesole M, Capelli D et al (2005) A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation. Biol Blood Marrow Transplant 11:627–636

    Article  Google Scholar 

  55. Olivieri A, Scortechini I, Capelli D et al (2004) Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant 34:693–702

    Article  Google Scholar 

  56. Olivieri A, Brunori M, Capelli D et al (2004) Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 72:10–17

    Article  Google Scholar 

  57. Montanari M, Capelli D, Poloni A et al (2003) Long-term hematologic reconstitution after autologous peripheral blood progenitor cell transplantation: a comparison between controlled-rate freezing and uncontrolled-rate freezing at 80 degrees C. Transfusion 43:42–49

    Article  Google Scholar 

  58. Olivieri A, Capelli D, Montanari M et al (2001) Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience. Bone Marrow Transplant 27:1189–1195

    Article  Google Scholar 

  59. Capelli D, Santini G, De Souza C et al (2000) Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study. Br J Haematol 110:300–307

    Article  Google Scholar 

  60. Bordignon C, Carlo-Stella C, Colombo MP et al (1999) Cell therapy: achievements and perspectives. Haematologica 84:1110–1149

    Google Scholar 

  61. Lemoli RM, Martinelli G, Olivieri A et al (1999) Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study. Br J Haematol 107:419–428

    Article  Google Scholar 

  62. Offidani M, Corvatta L, Olivieri A et al (1999) Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. Bone Marrow Transplant 24:1079–1087

    Article  Google Scholar 

  63. Aglietta M, Bertolini F, Carlo-Stella C et al (1998) Ex vivo expansion of hematopoietic cells and their clinical use. Haematologica 83:824–848

    Google Scholar 

  64. Olivieri A, Offidani M, Montanari M et al (1998) Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 83:329–337

    Google Scholar 

  65. Olivieri A, Offidani M, Ciniero L et al (1994) Optimization of the yield of PBSC for autotransplantation mobilized by high-dose chemotherapy and G-CSF: proposal for a mathematical model. Bone Marrow Transplant 14:273–278

    Google Scholar 

  66. Corradini P, Tarella C, Olivieri A et al (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75–82

    Article  Google Scholar 

  67. Chiusolo P, Bug G, Olivieri A et al (2018) A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transplant 24:1243–1249

    Article  Google Scholar 

  68. Eder S, Labopin M, Finke J et al (2017) Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. Bone Marrow Transplant 52:238–244

    Article  Google Scholar 

  69. Olivieri J, Mancini G, Goteri G et al (2016) Reversal of poor graft function with iron-chelating therapy after allogeneic transplantation for severe aplastic anemia. Leuk Lymphoma 57:965–968

    Article  Google Scholar 

  70. Corradini P, Vitolo U, Rambaldi A et al (2014) Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28:1885–1891

    Article  Google Scholar 

  71. Mariotti J, Maura F, Spina F et al (2014) Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 20:885–890

    Article  Google Scholar 

  72. Corradini P, Zallio F, Mariotti J et al (2005) Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. J Clin Oncol 23:6690–6699

    Article  Google Scholar 

  73. Poloni A, Leoni P, Buscemi L et al (2006) Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia 20:329–335

    Article  Google Scholar 

  74. Poloni A, Leoni P, Curzi L et al (1999) Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery. Exp Hematol 27:1548–1556

    Article  Google Scholar 

  75. Olivieri A, Poloni A, Montanari M et al (1997) Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide. J Hematother 6:137–144

    Article  Google Scholar 

  76. Poloni A, Maurizi G, Serrani F et al (2012) Human AB serum for generation of mesenchymal stem cells from human chorionic villi: comparison with other source and other media including platelet lysate. Cell Prolif 45:66–75

    Article  Google Scholar 

  77. Poloni A, Maurizi G, Babini L et al (2011) Human mesenchymal stem cells from chorionic villi and amniotic fluid are not susceptible to transformation after extensive in vitro expansion. Cell Transplant 20:643–654

    Article  Google Scholar 

  78. Poloni A, Maurizi G, Rosini V et al (2009) Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow. Cytotherapy 11:153–162

    Article  Google Scholar 

  79. Poloni A, Rosini V, Mondini E et al (2008) Characterization and expansion of mesenchymal progenitor cells from first-trimester chorionic villi of human placenta. Cytotherapy 10:690–697

    Article  Google Scholar 

  80. Poloni A, Maurizi G, Leoni P et al (2012) Human dedifferentiated adipocytes show similar properties to bone marrow-derived mesenchymal stem cells. Stem Cells 30:965–974

    Article  Google Scholar 

  81. Maurizi G, Della Guardia L, Maurizi A et al (2018) Adipocytes properties and crosstalk with immune system in obesity-related inflammation. J Cell Physiol 233:88–97

    Article  Google Scholar 

  82. Maurizi G, Poloni A, Mattiucci D et al (2017) Human white adipocytes convert into “rainbow” adipocytes in vitro. J Cell Physiol 232:2887–2899

    Article  Google Scholar 

  83. Poloni A, Maurizi G, Mattiucci D et al (2015) Biosafety evidence for human dedifferentiated adipocytes. J Cell Physiol 230:1525–1533

    Article  Google Scholar 

  84. Poloni A, Maurizi G, Anastasi S et al (2015) Plasticity of human dedifferentiated adipocytes toward endothelial cells. Exp Hematol 43:137–146

    Article  Google Scholar 

  85. Poloni A, Maurizi G, Foia F et al (2015) Glial-like differentiation potential of human mature adipocytes. J Mol Neurosci 55:91–98

    Article  Google Scholar 

  86. Poloni A, Maurizi G, Serrani F et al (2013) Molecular and functional characterization of human bone marrow adipocytes. Exp Hematol 41(558–566):e552

    Google Scholar 

  87. Mattiucci D, Maurizi G, Izzi V et al (2018) Bone marrow adipocytes support hematopoietic stem cell survival. J Cell Physiol 233:1500–1511

    Article  Google Scholar 

  88. Mattiucci D, Naveiras O, Poloni A (2018) Bone marrow “yellow” and “red” adipocytes’’: good or bad cells? Curr Mol Biol Rep

    Google Scholar 

  89. Kansu E (2004) The pathophysiology of chronic graft-versus-host disease. Int J Hematol 79:209–215

    Article  Google Scholar 

  90. Zaja F, Bacigalupo A, Patriarca F et al (2007) Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40:273–277

    Article  Google Scholar 

  91. Zhang C, Todorov I, Zhang Z et al (2006) Donor CD4+ T and B cells in transplants induce chronic graft-versus host disease with autoimmune manifestations. Blood 107(7):2993–3001

    Article  Google Scholar 

  92. Patriarca F, Skert C, Sperotto A et al (2006) The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. Exp Hematol 34:389–396

    Article  Google Scholar 

  93. Abdollahi A, Li M, Ping G et al (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925–935

    Article  Google Scholar 

  94. Daniels CE, Wilkes MC, Edens M et al (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114:1308–1316

    Article  Google Scholar 

  95. Distler JH, Jungel A, Huber LC et al (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 56:311–322

    Article  Google Scholar 

  96. Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945–956

    Article  Google Scholar 

  97. Pavletic SZ, Martin P, Lee SJ et al (2006) Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12:252–266

    Article  Google Scholar 

  98. Olivieri A, Cimminiello M, Corradini P et al (2013) Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood 122:4111–4118

    Article  Google Scholar 

  99. Lee SJ, Wolff D, Kitko C et al (2015) Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 21:984–999

    Article  Google Scholar 

  100. Pierelli L, Bosi A, Olivieri A (2018) “Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion 58:217–222

    Article  Google Scholar 

  101. Giaccone L, Mancini G, Mordini N et al (2018) ‘Real-life’ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 53:58–63

    Article  Google Scholar 

  102. Perseghin P, Marchetti M, Messina C et al (2013) Best practice recommendations in: (1) Peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Societa Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Transfus Apher Sci 48:195–196

    Google Scholar 

  103. Poloni A, Sartini D, Emanuelli M et al (2011) Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning. Cytokine 53:376–383

    Article  Google Scholar 

  104. Patriarca F, Sperotto A, Damiani D et al (2004) Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89:1352–1359

    Google Scholar 

  105. Marinelli Busilacchi E, Costantini A, Viola N et al (2018) Immunomodulatory effects of tyrosine kinase inhibitor in vitro and in vivo study. Biol Blood Marrow Transplant 24:267–275

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Medica, Department of Clinical and Molecular Sciences, Università Politecnica Delle Marche, Via Tronto 10, 60126, Ancona, Italy

    Armando Gabrielli & Gianluca Moroncini

  2. Clinica Di Ematologia, Department of Clinical and Molecular Sciences, Università Politecnica Delle Marche, Via Tronto 10, 60126, Ancona, Italy

    Attilio Olivieri, Antonella Poloni & Elena Marinelli Busilacchi

Authors
  1. Armando Gabrielli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Attilio Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gianluca Moroncini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonella Poloni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Marinelli Busilacchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianluca Moroncini .

Editor information

Editors and Affiliations

  1. Department of Information Engineering (DII), Marche Polytechnic University, Ancona, Italy

    Sauro Longhi

  2. Department of Information Engineering (DII), Marche Polytechnic University, Ancona, Italy

    Andrea Monteriù

  3. Department of Information Engineering (DII), Marche Polytechnic University, Ancona, Italy

    Alessandro Freddi

  4. Department of Agricultural, Food and Environmental Sciences (D3A), Marche Polytechnic University, Ancona, Italy

    Lucia Aquilanti

  5. Ospedali Riuniti di Ancona, Ancona, Italy

    Maria Gabriella Ceravolo

  6. Department of Life and Environmental Sciences (DISVA), Marche Polytechnic University, Ancona, Italy

    Oliana Carnevali

  7. Department of Life and Environmental Sciences (DISVA), Marche Polytechnic University, Ancona, Italy

    Mario Giordano

  8. Ospedali Riuniti di Ancona, Ancona, Italy

    Gianluca Moroncini

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gabrielli, A., Olivieri, A., Moroncini, G., Poloni, A., Busilacchi, E.M. (2020). History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona. In: Longhi, S., et al. The First Outstanding 50 Years of “Università Politecnica delle Marche”. Springer, Cham. https://doi.org/10.1007/978-3-030-33832-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-33832-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-33831-2

  • Online ISBN: 978-3-030-33832-9

  • eBook Packages: EducationEducation (R0)

Publish with us

Policies and ethics

Search

Navigation